Lack of Compliance with EMHS Redistribution Guidelines in Ugandan Health Facilities

By Staff Writer

March 10, 2023

Introduction

In public health, efficient management of Essential Medicines and Health Supplies (EMHS) is crucial. In Uganda, EMHS redistribution is a vital process that ensures healthcare facilities are equipped to serve their communities effectively.  Execution of the EMHS redistribution guidelines was lacking in public health facilities in Uganda. Just one third (33%) of the health facilities conformed with the EMHS redistribution guidelines.

Understanding EMHS Redistribution

EMHS redistribution involves transferring unused, non-expired health commodities from overstocked facilities to those in dire need. This system is particularly important in Uganda, where disparities in healthcare provision are common. By redistributing resources, the country can better manage its limited supplies, prevent wastage, and ensure a more equitable distribution of medical essentials.

The Current State of EMHS in Uganda

Despite the government’s efforts, the healthcare sector often encounters stock-outs and excesses in EMHS. With a budget that falls short of the Abuja Declaration’s recommendations, the sector struggles to meet the demands of its populace. Redistribution of EMHS is a strategy to mitigate these challenges, yet compliance with guidelines remains low, at just 33.3%.

Challenges in Redistribution

A primary obstacle in the redistribution process is the lack of guideline dissemination, resulting in significant knowledge gaps among healthcare staff. This study found that respondents who reported that the guidelines were never shared with staff in other departments were 88% less likely to comply. Failure to share guidelines further led to staff knowledge gaps, as over half (54.5%) of the staff did not know about the guidelines. Furthermore, unclear financial responsibilities and bureaucratic procedures further hinder the efficient movement of supplies. These systemic issues contribute to stock discrepancies and ultimately affect patient care.

Strategies for Improvement

To address these challenges, it is essential to ensure that guidelines are accessible and understood by all relevant staff. Financial transparency and streamlined procedures can alleviate some of the bottlenecks in the system. Furthermore, consistent delivery schedules from the National Medical Stores can reduce the uncertainty that leads to stock hoarding. To improve compliance with redistribution:

  1. Allocation of funds for transporting medicines should be considered by the district.
  2. Health facility managers should raise awareness among staff working in stores concerning the redistribution process.
  3. The District Health Officer (DHO) should make it a priority to routinely monitor health facilities particularly to avoid the issue of medicine stock-outs and overstocking.

Conclusion

Enhancing EMHS redistribution requires a multifaceted approach, focusing on education, financial planning, and procedural efficiency. By tackling these issues, Uganda can move towards a more resilient and responsive healthcare system.

 

Reference url

Recent Posts

TLX250-CDx imaging agent
      

Zircaix: A Potential Breakthrough in Kidney Cancer Diagnosis

🔍 Could a new imaging agent revolutionize kidney cancer diagnosis?

The FDA’s acceptance of the Biologics License Application for TLX250-CDx marks a significant milestone in the fight against clear cell renal cell carcinoma (ccRCC). This investigational PET imaging tool promises non-invasive, high-accuracy diagnostics, which could lead to improved patient outcomes and better-targeted treatment plans.

Curious about its potential impact on healthcare and market dynamics? Dive into the full article to learn more!

#SyenzaNews #medicalimaging #oncology #HealthcareInnovation

personalized cancer vaccine
         

Personalized Cancer Vaccine in High-Risk Kidney Cancer Patients

🌟 Could personalized cancer vaccines be the future of cancer treatment?

A recent phase I clinical trial has shown promising results for a personalized cancer vaccine in patients with high-risk clear cell renal cell carcinoma (RCC). All participants developed immune responses, and notably, none experienced recurrence at a median follow-up of over 40 months! With a favorable safety profile, this approach may pave the way for more effective adjuvant therapies in oncology.

Jump into the full findings and see how this advancement could change the landscape of cancer treatment!

#SyenzaNews #oncology #biotechnology #innovation

ivonescimab clinical trials
    

Advancing Cancer Treatment: Ivonescimab’s Potential and Strategic Collaboration with Pfizer

🚀 Exciting news in the fight against cancer!

Summit Therapeutics has announced a groundbreaking collaboration with Pfizer to launch clinical trials for ivonescimab, an innovative PD-1/VEGF bispecific antibody. This partnership aims to evaluate the safety and effectiveness of ivonescimab in combination with Pfizer’s antibody drug conjugates across various solid tumors, including non-small cell lung cancer. 🌟

To learn more about this promising development and its potential impact on oncology treatment, dive into the full article!

#SyenzaNews #oncology #clinicaltrials #innovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.